Vegetable-Source Glucosamine Supplier Licenses Patent for New Manufacturing Method
ENI has signed a licensing agreement for a new patented method of producing glucosamine through a microbial fermentation process.
Photo © iStockphoto.com/David Marchal
Glucosamine, a popular ingredient in joint health dietary supplements that is often derived from shellfish, has been dogged by concerns of raw material pollution and allergic side effects. Shellfish-derived glucosamine was even the target of intensified regulatory restrictions last year. But sourcing glucosamine from non-animal sources may sidestep many of these issues.
Glucosamine supplier Ethnical Naturals Inc. (ENI; San Anselmo, CA) has licensed a new patented method for producing N-acetyl glucosamine and glucosamine through a microbial fermentation process. The license agreement, which ENI signed with Arkion Life Sciences (ALS; New Castle, DE), enables ENI to make, sell, import, and export the vegetable-source glucosamine wherever ALS has issued parents and patent applications. The vegetable-source glucosamine will be marketed under ENI’s GreenGrown Glucosamine brand.
“Almost all glucosamine today is produced as a by-product of the Asian shellfish industry, which is often considered ecologically unsustainable,” says Cal Bewicke, CEO, ENI. “Producing glucosamine from this shellfish residue also results in high acid waste products which are hard to dispose of. GreenGrown offers an alternative to these problems.”
ENI says its new vegetable-source glucosamine option may allow a market option for supplement manufacturers looking to reach vegetarian and vegan consumers, or those suffering from allergies. Manufacturers using this vegetable-source glucosamine could avoid the need for those pesky allergy label warnings, says ENI.
Read more:
Glucosamine: Still Standing Strong?
Ethical Naturals Develops Test Method for Glucosamine Sources
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
